Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572100 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT04572100 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 50 participants.
The verdict
NCT04572100, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage after therapy and reduce the amount of additional radiotherapy or chemotherapy treatment the participant may need. This study will also examine ways to reduce overall side effects of treatment using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- OTHER Transoral Robotic Surgery (TORS) or Radiotherapy
- OTHER Chemotherapy and Low-Dose Radiotherapy
- OTHER Chemotherapy and High-Dose Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572100
The ClinicalTrials.gov registry entry for NCT04572100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT04572100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04572100 about?
NCT04572100 is a clinical study titled "Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer". Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage after therapy and reduce the amount of additional radiotherapy or chemot...
What is the current status of trial NCT04572100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2020-10-01. Estimated completion is 2023-01-09.
What interventions are being tested in trial NCT04572100?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Transoral Robotic Surgery (TORS) or Radiotherapy (OTHER), Chemotherapy and Low-Dose Radiotherapy (OTHER), Chemotherapy and High-Dose Radiotherapy (OTHER).
Who is sponsoring clinical trial NCT04572100?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.